CureVac To Withdraw First-generation COVID-19 Vaccine Candidate From EMA Approval Process

CureVac N.V. (CVAC) has decided to withdraw the company's first-generation COVID-19 vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency due to potential overlap with approval timelines for a second-generation candidate. The company will focus its COVID-19 vaccine development towards the development of second-generation mRNA vaccine candidates in collaboration with GSK.

CureVac noted that the existing Advanced Purchase Agreement with the European Commission will cease.

Shares of CureVac were down 12% in pre-market trade on Tuesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Home improvement company Lowe's and pet retailer Petco Health and Wellness Co. are set to launch a pilot store-in-store program whereby a total home solution will be offered to customers by bringing home improvement as well as pet care products, services and expertise together under the same roof. Chevron Corporation (CVX) reported fourth quarter profit of $5.1 billion or $2.63 per share, compared to a loss of $665 million or $0.33 per share, previous year. The company's U.S. upstream operations earned $2.97 billion, compared to $101 million, a year ago. The company said the improvement was primarily... While reporting financial results for the fourth quarter on Friday, Colgate-Palmolive Co. (CL) initiated its earnings and sales growth guidance for the full-year 2022. For fiscal 2022, the company now expects earnings per share to grow in double-digit percentage and adjusted earnings per share growth...
Follow RTT